Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma amended its definitive merger agreement with InnocsAI to allow the deal to close prior to stockholder approval, with an expected closing date of July 2, 2026. The transaction implies a value of approximately $320 million, with consideration consisting of common stock issued at $0.20 per share and non-voting convertible preferred stock. InnocsAI equity holders will receive up to 19.99% of Liminatus' outstanding common stock immediately at closing.
Key figures
- Deal Value Usd
- $320 million
- Offering Price
- 0.2
- Closing date
- July 2, 2026
- Cvr percentage
- 20% of future net proceeds from strategic transactions
- Immediate dilution cap
- 19.99% of outstanding common stock
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.